Ikena Oncology. has been granted a patent for AHR agonists and their compositions, which are designed to reduce the risk of disorders related to angiogenesis and inflammation through specific administration methods. GlobalData’s report on Ikena Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ikena Oncology, Cancer treatment biomarkers was a key innovation area identified from patents. Ikena Oncology's grant share as of June 2024 was 11%. Grant share is based on the ratio of number of grants to total number of patents.
Ahr agonists for treating angiogenesis and inflammatory disorders
The granted patent US12030876B2 outlines a method for reducing the risk of disorders associated with angiogenesis and inflammation in patients. The method involves administering specific compounds, particularly those represented by various chemical formulas, including Formula (I) and its derivatives such as Formulae (III), (IV), (V), (VIII), and (X). The claims detail the structural components of these compounds, specifying variations in substituents (R groups) and ring structures (Ring B and Ring C) that may influence their therapeutic efficacy. Notably, the compounds can include a range of functional groups, such as halogens, amines, and hydroxyls, which may enhance their biological activity.
Additionally, the patent identifies specific disorders that may benefit from this treatment approach. Angiogenesis-related conditions mentioned include retinopathy, psoriasis, rheumatoid arthritis, obesity, and cancer. Inflammatory disorders covered by the claims encompass a wide array of conditions, such as acne vulgaris, asthma, autoimmune diseases, and various forms of inflammatory bowel disease, among others. The comprehensive nature of the claims suggests a broad potential application for these compounds in managing both angiogenesis and inflammation-related health issues.
To know more about GlobalData’s detailed insights on Ikena Oncology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
